- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04434456
Carotid Artery Aneurysm Treatment Using CGuard Divert-And-Heal Strategy (C-HEAL)
Prospective Observational Study of CGuard MicroNet Covered Stent System Use as a Flow Diverter in the Endovascular Exclusion of Carotid Artery Aneurysms. (CGuard Divert-and-HEAL C-HEAL)
Non-randomized, single arm, open label, academic observational study of CGuard MicroNet covered stent system use to achieve endovascular lumen reconstruction in carotid artery aneurysms with indications for treatment (enlarging and/or dissecting / symptomatic).
Jagiellonian University Medical College research project.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Carotid artery aneurysm (CAA) is a relatively infrequent, but significant clinical condition with numerous diagnostic and therapeutic implications. CAA affects laminal flow in the carotid artery implicating the risk of thrombus formation in the aneurysm cavity, and subsequent ischemic stroke from distal embolization. Another important clinical problem related to the CAA is a possible aneurysm dissection and rupture. Symptomatic CAA and increasing dimensions of CAA institute unquestioned indications for the CAA treatment.
Surgical carotid aneurysm repair bears a significant risk (periprocedural stroke, cranial nerve damage, carotid artery ligation). Therefore endovascular techniques of CAA exclusion were developed. Covered stents, stent-grafts, and combined stenting and aneurysm embolization with coils were applied. However, covered stents were demonstrated to increase the restenosis risk, and other complications such as CAA neck endo-leak.
Newer technique involves the flow diversion by implantation of stent in dense-structured stent (such as Wallstent) or stent-in-stent implantation. In this case a luminary flow dominates over aneurysm filling, which is limited by stent structure. Gradual thrombosis and occlusion of aneurysm cavity and healing of aneurysm follows.This method disadvantage was related to necessity of double stent load and increased restenosis risk (double metal layer).
These issues were addressed only recently by the double layer mesh stents that demonstrate natural flow diverting capabilities. CGuard Stent system is a self-expandable stent covered with PET mesh (MicroNet) that prevents plaque protrusion into the vessel lumen. In addition, in low flow conditions MicroNet can act as the flow diverter. These stents are routinely implanted in elevated risk plaques in high reference centers in Europe.
Several published observations indicate the CGuard stent also demonstrates flow-diverting capabilities, but the systematic observation of such application was not performed.
C-HEAL is a non-randomized, single arm, open label academic observational study of CGuard stent implantation in carotid arteries in patients with symptomatic, dissecting or enlarging carotid artery aneurysm. Procedures are performed according to the center routine, with application of proximal or distal embolic protection device (if feasible), and standard pharmacotherapy according to the current guidelines.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Maloplska
-
Kraków, Maloplska, Poland, 31-202
- Recruiting
- Department of Cardiac and Vascular Diseases, The John Paul II Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
General
Inclusion Criteria:
- Patients older than 18 years, eligible for endovascular carotid artery aneurysm treatment with Micronet covered stent per Vascular Team evaluation, according to local standards
- Written, informed consent to participate
- Agreement to attend protocol required (standard) follow up visits and examinations
Exclusion Criteria:
- Preferred treatment other than stenting (surgery or conservative treatment / observation) per Vascular Team evaluation
- Life expectancy <1 year (e.g. active neoplastic disease).
- Chronic kidney disease with creatinine > 3.0 mg/dL.
- Myocardial infarction in 72 hours proceeding the stenting procedure (if possible, postponing the procedure)
- Pregnancy (positive pregnancy test)
- Coagulopathy.
- History of uncontrolled contrast media intolerance
Angiographic
Inclusion Criteria:
- Carotid artery aneurysm confirmed on angiography - symptomatic, dissected or enlarging
- Aneurysm eligible for endovascular treatment per Vascular Team evaluation (according to current standards, guidelines and study center practice)
Exclusion Criteria:
- Unsuccessful true lumen engagement
- Aneurysm neck anatomy precluding healthy-to-healthy coverage with stent
- Anatomic variants precluding stent implantation
- Mobile (free-floating) plaque elements in aorta or arteries proximal to target lesion
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CGuard stenting (interventional)
CGuard implantation in the carotid artery with aneurysm requiring intervention
|
CGuard stent implantation in the carotid artery with symptomatic, dissecting or enlarging aneurysm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of successful aneurysm exclusion
Time Frame: 6 months
|
Successful aneurysm cavity exclusion and endovascular lumen reconstruction on routine, non-invasive CT angiography
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of procedural success
Time Frame: Peri-procedural
|
Procedural success defined as: Technical success (successful MicroNet covered stent delivery and implantation with complete aneurysm necks coverage) and Clinical success (no complications)
|
Peri-procedural
|
Rate of In-hospital MACNE (major adverse cardiac and neurological events)
Time Frame: 48 hrs or until discharge
|
In-hospital MACNE (death, stroke, myocardial infarction)
|
48 hrs or until discharge
|
MACNE at 30 days
Time Frame: 30 days
|
MACNE at 30 days (death, stroke, myocardial infarction)
|
30 days
|
Number of peri-procedural complications
Time Frame: 48 hrs or until discharge
|
Any complications occurring up to 48 hours post procedure
|
48 hrs or until discharge
|
Rate of clinical efficacy at 6 months
Time Frame: 6 months
|
Clinical efficacy defined as successful aneurysm exclusion and no procedure related complications
|
6 months
|
Rate of clinical efficacy at 12 months
Time Frame: 12 months
|
Clinical efficacy defined as successful aneurysm exclusion and no procedure related complications
|
12 months
|
Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in the target vessel segment
Time Frame: 6 months
|
Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in ultrasound evaluation of target vessel segment (if amenable to duplex Doppler examination)
|
6 months
|
Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in target vessel segment
Time Frame: 12 months
|
Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in ultrasound evaluation of target vessel segment (if amenable to duplex Doppler examination)
|
12 months
|
Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in target vessel segment
Time Frame: 24 months
|
Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in ultrasound evaluation of target vessel segment (if amenable to duplex Doppler examination)
|
24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-HEAL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carotid Artery Aneurysm
-
UMC UtrechtRecruitingExtracranial Carotid Artery AneurysmNetherlands
-
UMC UtrechtRecruiting
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloUnknownCerebral Aneurysm | Brain Aneurysm | Aneurysm, Middle Cerebral Artery | Aneurysm, Anterior Communicating Artery | Aneurysm, Posterior Communicating Artery | Aneurysm, Carotid ArteryBrazil
-
Tartu University HospitalCompletedPeripheral Artery Disease | Abdominal Aortic Aneurysm | Carotid Artery StenosisEstonia
-
Universitair Ziekenhuis BrusselActive, not recruitingCarotid Artery Plaque | Aneurysm | Aortic AneurysmBelgium
-
Philips Clinical & Medical Affairs GlobalCompletedCarotid Stenosis | Abdominal Aortic Aneurysm (AAA) | Thoracic Aortic Aneurysm (TAA) | Visceral Artery AneurysmUnited States
-
Erik DebingCompletedAbdominal Aortic Aneurysm | Carotid Artery Stenosis | EpidemiologyBelgium
-
Seoul National University HospitalSamsung Medical Center; Asan Medical Center; Seoul National University Bundang... and other collaboratorsActive, not recruitingUnruptured Aneurysm of Carotid ArteryKorea, Republic of
-
University of MiamiTemporarily not availablePseudoaneurysm, Carotid | PseudoaneurysmUnited States
-
Azienda Ospedaliera SS. Antonio e Biagio e Cesare...Scuola di Specializzazione in Psicologia Clinica dell'Università degli Studi... and other collaboratorsCompletedCarotid Stenosis | Spinal Fusion | Abdominal Aortic Aneurysm | Colectomy | Quadrantectomies
Clinical Trials on CGuard stent implantation
-
InspireMDRecruitingCarotid Artery StenosisUnited States, Poland
-
John Paul II Hospital, KrakowInspireMDRecruitingCarotid Artery DiseasesPoland
-
Shanghai Zhongshan HospitalUnknownPercutaneous Coronary Intervention | Acute Myocardial InfarctionChina
-
Terumo Europe N.V.Active, not recruitingSuperficial Femoral Artery Disease | Popliteal Artery DiseaseSpain, Belgium, Germany, France, Netherlands
-
Ruijin HospitalShanghai Tong Ren Hospital; Shanghai Pulmonary Hospital, Shanghai, China; Ruijin...UnknownAirway Disease | Fistula Bronchial | Fistula, GastricChina
-
Southeast University, ChinaScience and Technology Department of Jiangsu ProvinceCompletedCoronary Artery Disease | Coronary Artery Disease ProgressionChina
-
Boston Scientific CorporationCompletedAtherosclerosis of Native Arteries of the Extremities, UnspecifiedBelgium, United States, United Kingdom, Japan, Austria, Canada, Germany
-
Medtronic VascularMedtronic Bakken Research CenterCompletedCoronary Artery DiseaseNetherlands
-
Boston Scientific CorporationKIKACompletedThrombosis | Intermittent Claudication | Arterial Occlusive Disease | Atherosclerotic DiseaseBelgium, Canada, Czech Republic, Netherlands, Poland
-
Seoul National University HospitalB. Braun Melsungen AGUnknown